Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.92M | $3.46M | $4.99M | $3.52M | $1.83M | $4.34M | $14.7M | $8.95M | $9.50M | $14.6M |
| Revenue growth | — | -41.6% | 44.2% | -29.5% | -48.1% | 137.7% | 238.7% | -39.2% | 6.2% | 53.2% |
| Gross profit | $5.57M | $3.29M | $4.69M | $3.10M | $1.44M | $2.92M | $14.0M | $8.27M | — | — |
| Gross margin | 94.0% | 95.1% | 93.9% | 88.3% | 78.9% | 67.2% | 95.0% | 92.5% | — | — |
| Operating income | -$59.0M | -$38.9M | -$41.8M | -$38.9M | -$26.4M | -$49.2M | -$22.5M | -$24.7M | -$21.5M | -$36.6M |
| Operating margin | -995.6% | -1125.0% | -837.9% | -1106.0% | -1448.4% | -1133.6% | -153.2% | -276.5% | -226.1% | -251.6% |
| Net income | $33.6M | -$20.0M | -$46.0M | -$11.7M | -$20.6M | -$43.0M | -$26.3M | -$21.5M | -$18.6M | -$63.5M |
| Net margin | 566.8% | -577.7% | -922.0% | -333.1% | -1130.8% | -991.0% | -178.7% | -240.2% | -195.9% | -436.5% |
| EPS (diluted) | $0.34 | -$0.17 | -$0.36 | -$0.08 | -$0.14 | -$0.26 | -$0.15 | -$0.12 | -$0.09 | -$0.28 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$42.3M | -$30.5M | -$30.9M | -$31.9M | -$19.8M | -$23.6M | $1.06M | -$28.6M | -$23.1M | -$18.9M |
| Capital expenditures | $2.25M | $1.33M | $556K | $440K | $64.0K | $340K | $413K | $674K | $565K | $522K |
| Free cash flow | -$44.6M | -$31.8M | -$31.4M | -$32.4M | -$19.8M | -$23.9M | $646K | -$29.2M | -$23.7M | -$19.4M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $22.1M | $36.8M | $23.6M | $9.50M | $32.6M | $55.7M | $11.4M | $35.4M | $45.8M | $40.8M |
| Total assets | $143M | $173M | $102M | $125M | $108M | $175M | $124M | $101M | $113M | $113M |
| Total liabilities | $12.1M | $8.98M | $9.41M | $14.2M | $12.8M | $83.6M | $51.7M | $39.0M | $36.2M | $69.2M |
| Shareholders' equity | $118M | $163M | $93.8M | $113M | $96.2M | $92.2M | $73.3M | $63.4M | $78.4M | $44.5M |
| Retained earnings | -$196M | -$216M | -$262M | -$273M | -$294M | -$337M | -$363M | -$385M | -$403M | -$467M |
| Shares (wtd avg diluted) | 99.6M | 114M | 127M | 150M | 153M | 165M | 170M | 173M | 200M | 230M |
Every figure is extracted from Lineage Cell Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.